O'Gorman Tessa, Lambert John S, McHugh Tina, Cullen Walter, Avramovic Gordana, Federico Raffaele, West Bernard, O'Kelly Brendan, Vidal Louise, Farrell Jeremy, Broughan John, O'Connor Eileen, Woo James
Mater Misericordiae University Hospital, 7 Dublin, Ireland.
School of Medicine, University College Dublin, 4 Dublin, Ireland.
Pathogens. 2022 Nov 27;11(12):1428. doi: 10.3390/pathogens11121428.
Hepatitis C Virus (HCV) disproportionately affects people who inject drugs, migrants, prisoners and the homeless. An integrated, peer-led model of care involving primary and secondary care is required to enhance the identification and treatment of HCV in these marginalised groups. HepCare Plus builds on the network and achievements of HepCare Europe (a co-funded Third Health Programme of the European Union/Health Service Executive project). It further identifies those not accessing care and facilitates prompt assessment and treatment of those diagnosed with HCV, with the aid of a peer support worker (PSW) and a community HCV nurse specialist. Of 109 individuals identified and assessed for HCV treatment, 100 commenced HCV treatment. Despite interruptions to treatment (COVID-19 pandemic and national health service cyberattack) there was a high-level of treatment completion with PSW engagement (98%, n = 98). Eighty (73%) individuals were previously aware of a positive HCV status, highlighting the ongoing need to address barriers preventing marginalised groups from engaging with care. HepCare Plus reiterates the defining role of peer-led community interventions in HCV treatment engagement and the need for continuous open-ended HCV care. It provides a sustainable framework to meaningfully combat HCV and achieve the United Nations Sustainable Development Goal of HCV elimination by 2030.
丙型肝炎病毒（HCV）对注射吸毒者、移民、囚犯和无家可归者的影响尤为严重。需要一种由同伴主导的综合护理模式，涵盖初级和二级护理，以加强对这些边缘化群体中HCV的识别和治疗。HepCare Plus建立在HepCare Europe（欧盟/卫生服务执行项目共同资助的第三个卫生计划）的网络和成就基础之上。它进一步识别那些未接受护理的人群，并在同伴支持工作者（PSW）和社区HCV护士专家的帮助下，为那些被诊断为HCV的患者提供及时的评估和治疗。在109名被识别并评估接受HCV治疗的个体中，有100人开始了HCV治疗。尽管治疗受到干扰（新冠疫情和国家医疗服务网络攻击），但在PSW的参与下，治疗完成率很高（98%，n = 98）。80名（73%）个体此前已知HCV检测呈阳性，这凸显了持续解决阻碍边缘化群体接受护理的障碍的必要性。HepCare Plus重申了同伴主导的社区干预在HCV治疗参与中的决定性作用，以及持续提供开放式HCV护理的必要性。它提供了一个可持续的框架，以切实抗击HCV，并实现联合国到2030年消除HCV的可持续发展目标。
